桐昆股份(601233.SH)擬對桐昆投資繼續增資25億元
格隆匯6月4日丨桐昆股份(601233.SH)公佈,桐昆投資設立之初註冊資本為30億元,由公司100%出資。考慮到浙石化項目建設大規模展開,所需資金巨大,故經公司董事會、股東大會審議批准,由公司對桐昆投資先後進行了兩次增資。增資完成後,桐昆投資註冊資本現已變更為80億元。
現考慮到浙石化在一期項目投產的基礎上,正積極推進二期項目建設,後續還需大量資金,除銀行配套的項目貸款資金之外,還需浙石化各股東繼續以資本金形式投入項目建設。公司擬在現桐昆投資80億元註冊資本的基礎上,繼續對桐昆投資進行增資25億元。增資完成後,桐昆投資註冊資本變更為105億元。公司繼續持有桐昆投資100%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.